Sorafenib attenuates p21 in kidney cancer cells and augments cell death in combination with DNA-damaging chemotherapy

High throughput screening of a small molecule one-bead-one-compound combinatorial library to identify attenuators of p21 as chemotherapy sensitizers

(2010) See-Hyoung Park et al.   CANCER BIOLOGY & THERAPY

Doxorubicin Plus Sorafenib vs Doxorubicin Alone in Patients With Advanced Hepatocellular Carcinoma

(2010) Ghassan K. Abou-Alfa et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Sorafenib

(2009) Gillian M. Keating et al.   DRUGS

Sorafenib has soluble epoxide hydrolase inhibitory activity, which contributes to its effect profile in vivo

(2009) J.-Y. Liu et al.   MOLECULAR CANCER THERAPEUTICS

Phase I and pharmacokinetic study of sorafenib, an oral multikinase inhibitor, in Japanese patients with advanced refractory solid tumors

(2008) Hironobu Minami et al.   CANCER SCIENCE

Enhanced Antitumor Therapy by Inhibition of p21waf1 in Human Malignant Mesothelioma

(2008) R. Lazzarini et al.   CLINICAL CANCER RESEARCH

Antisense Attenuation of p21 Sensitizes Kidney Cancer to Apoptosis in Response to Conventional DNA Damaging Chemotherapy Associated With Enhancement of Phospho-p53

(2008) See-Hyoung Park et al.   JOURNAL OF UROLOGY